Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Klein, Katrin [VerfasserIn]   i
 Süsal, Caner [VerfasserIn]   i
 Schäfer, Sebastian Markus [VerfasserIn]   i
 Becker, Luis Eduardo [VerfasserIn]   i
 Beimler, Jörg [VerfasserIn]   i
 Schwenger, Vedat [VerfasserIn]   i
 Zeier, Martin [VerfasserIn]   i
 Schemmer, Peter [VerfasserIn]   i
 Macher-Göppinger, Stephan [VerfasserIn]   i
 Scherer, Sabine [VerfasserIn]   i
 Opelz, Gerhard [VerfasserIn]   i
 Morath, Christian [VerfasserIn]   i
Titel:Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis
Verf.angabe:Katrin Klein, Caner Süsal, Sebastian M. Schäfer, Luis Eduardo Becker, Jörg Beimler, Vedat Schwenger, Martin Zeier, Peter Schemmer, Stephan Macher-Goeppinger, Sabine Scherer, Gerhard Opelz, Christian Morath
E-Jahr:2013
Jahr:26 January 2013
Umfang:4 S.
Fussnoten:Gesehen am 08.06.2022
Titel Quelle:Enthalten in: Atherosclerosis. Supplements
Ort Quelle:Amsterdam [u.a.] : Elsevier Science, 2000
Jahr Quelle:2013
Band/Heft Quelle:14(2013), 1, Seite 199-202
ISSN Quelle:1878-5050
Abstract:Objective - Due to increasing waiting times for deceased donor kidneys, living donor kidney transplantation is increasingly performed in the presence of donor-specific antibodies (DSA). - Methods - Twenty-three patients with Luminex-detected DSA were successfully desensitized by anti-CD20 therapy and immunoadsorption (N = 19) or plasmapheresis (N = 4) and received a kidney transplant from a living donor. Twelve of the 23 patients (52%) had a positive CDC and/or ELISA crossmatch result before desensitization. Six patients were negative in CDC as well as ELISA screening but positive in Luminex for DSA. - Results - The 23 patients received a median of 8 apheresis treatments before and 5 treatments after transplantation. Induction therapy was performed with either thymoglobulin (N = 11) or basiliximab (N = 12). The 2-year graft survival rate was 100%. At last follow up, a median of 12 months after transplantation, median serum creatinine was 1.42 mg/dL, median MDRD-GFR 59.5 mL/min/1.73 m2, and median urinary protein-to-creatinine ratio 0.12. Ten out of fourteen patients (71%) who had completed the first year after transplantation by the time of analysis had no DSA by day 360. Acute T-cell mediated rejection was diagnosed in one patient (4%), and antibody-mediated changes were found in 5 patients (22%). Four out of these 5 patients showed evidence of persistent (N = 2) or reemerging plus/minus de novo DSA (N = 2) on day 360, and the 2 patients with persistent DSA lost their allograft subsequently on days 750 and 810, respectively. Infectious complications were infrequent. - Conclusions - Our previously described treatment algorithm for desensitization of living donor kidney transplant recipients with DSA results in good graft outcomes with a low rate of side effects.
DOI:doi:10.1016/j.atherosclerosissup.2012.10.030
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.atherosclerosissup.2012.10.030
 Volltext: https://www.sciencedirect.com/science/article/pii/S1567568812000414
 DOI: https://doi.org/10.1016/j.atherosclerosissup.2012.10.030
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Desensitization
 Donor-specific antibodies
 Immunoadsorption
 Kidney transplantation
 Living donation
 Rituximab
K10plus-PPN:1751707121
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68713983   QR-Code
zum Seitenanfang